This 6-part podcast mini-series, organized and supported by Bayer, is intended for healthcare professionals practicing in the US. Our aim is to raise awareness of the importance of early diagnosis and appropriate management of chronic kidney disease (CKD) in patients with type 2 diabetes in order to slow progression of CKD and reduce the risk of premature cardiovascular morbidity and mortality.
CKD diagnosis relies on routine screening as early-stage CKD is often asymptomatic.
Risk of developing kidney disease differs among individuals, with race, ethnicity, and socioeconomic disadvantages being risk factors.
Majority of patients with CKD will die from cardiovascular disease before reaching ESKD.
Early detection and appropriate intervention of CKD associated with T2D has the potential to slow CKD progression and improve patient outcomes.
This is episode 1 of a 6-part podcast mini-series, organized and supported by Bayer, is intended for healthcare professionals practicing in the US. Our aim is to raise awareness of the importance of early diagnosis and appropriate management of chronic kidney disease (CKD) in patients with type 2 diabetes in order to slow progression of CKD and reduce the risk of premature cardiovascular morbidity and mortality.
Drs. Susanne B. Nicholas (Nephrologist and Professor of Medicine and Clinical Hypertension Specialist in the Division of Nephrology at UCLA) and Radica Alicic (Internist and Clinical Professor at the University of Washington) provide an overview of CKD diagnosis, risk factors, patient impact, and strategies to slow progression and improve outcomes in patients with T2D.